Jiangsu Sinopep-Allsino Biopharmaceutical (SH:688076) Xin Lang Cai Jing·2025-12-09 08:09Core Viewpoint - The ongoing legal case against Jiangsu Nuotai Aosaikeno Biopharmaceutical Co., Ltd. (ST Nuotai) involves allegations of false statements in securities, with investors seeking compensation for losses incurred due to these misrepresentations [1][4]. Group 1: Allegations of False Statements - Nuotai Biopharmaceutical's 2021 annual report contained false records, including a reported business income of 30 million yuan from a technology transfer to Zhejiang Huabei, which lacked the financial capability to pay for it [1][4]. - The technology transfer was deemed to lack commercial substance, leading to an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, representing 20.64% of the total profit disclosed for that period [1][4]. Group 2: Misrepresentation in Public Offering Documents - On December 12, 2023, Nuotai Biopharmaceutical issued a prospectus for a convertible bond offering of 434 million yuan, which included false financial information from the 2021 annual report [2][5]. - The prospectus disclosed that the inflated revenue and profit figures were included in the financial accounting information, constituting significant false content [2][5]. Group 3: Investor Compensation - Investors who purchased Nuotai Biopharmaceutical shares between April 28, 2022, and October 23, 2024, and still held them as of the latter date are eligible to seek compensation, subject to court verification [3][6]. - Required documentation for claims includes securities account information, stock reconciliation statements from April 1, 2022, to the present, and contact information [3][6].